Migraine

Patients who are hospitalized with stroke-like symptoms, but do not experience a stroke, may yet develop PTSD at a higher rate than patients who actually had a stroke, a speaker reported.

Older adults recently diagnosed with migraine were more than three times likely to be involved in a motor vehicle crash within a year compared with those who never had a migraine diagnosis, according to researchers.

Treatment with 100 mg of ubrogepant in the prodromal phase prevented development of headaches as soon as 24 hours post-dose compared with placebo, according to study co-author Peter J. Goadsby, MD, PhD, FRS.

Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.

Developments in spectacle lenses over the past year have revealed their efficacy beyond vision correction.

Among seven classes and 25 individual medications, triptans, ergots and anti-emetics were the most effective acute treatments for individuals with migraine, according to research published in Neurology.

Treatment with 100 mg ubrogepant was effective at curbing migraine attacks when administered during the prodromal phase compared with placebo, according to research from The Lancet.

Ajovy significantly reduced depression symptoms and monthly migraine days in a phase 4 study, with clinically meaningful improvements in disability outcomes, manufacturer Teva Pharmaceuticals announced in a press release.

AUSTIN, Texas — More than 80% of those dealing with migraine or severe headaches reported cognitive impairment, with the most common being concentration difficulty, according to a presenter at the American Headache Society annual meeting.